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Abstract
Background: Major depressive disorder (MDD) during pregnancy and postpartum depression are associated with
significant maternal and neonatal morbidity. While antidepressants are readily used in pregnancy, studies have
raised concerns regarding neurobehavioral outcomes in exposed infants. Omega-3 fatty acid supplementation,
most frequently from fish oil, has emerged as a possible treatment or prevention strategy for MDD in non-
pregnant individuals, and may have beneficial effects in pregnant women. Although published observational
studies in the psychiatric literature suggest that maternal docosahexaenoic acid (DHA) deficiency may lead to the
development of MDD in pregnancy and postpartum, there are more intervention trials suggesting clinical benefit
for supplementation with eicosapentaenoic acid (EPA) in MDD.
Methods/Design: The Mothers, Omega-3 and Mental Health study is a double blind, placebo-controlled,
randomized controlled trial to assess whether omega-3 fatty acid supplementation may prevent antenatal and
postpartum depressive symptoms among pregnant women at risk for depression. We plan to recruit 126 pregnant
women at less than 20 weeks gestation from prenatal clinics at two health systems in Ann Arbor, Michigan and
the surrounding communities. We will follow them prospectively over the course of their pregnancies and up to 6
weeks postpartum. Enrolled participants will be randomized to one of three groups: a) EPA-rich fish oil supplement
(1060 mg EPA plus 274 mg DHA) b) DHA-rich fish oil supplement (900 mg DHA plus 180 mg EPA; or c) a placebo.
The primary outcome for this study is the Beck Depression Inventory (BDI) score at 6 weeks postpartum. We will
need to randomize 126 women to have 80% power to detect a 50% reduction in participants’ mean BDI scores
with EPA or DHA supplementation compared with placebo. We will also gather information on secondary
outcome measures which will include: omega-3 fatty acid concentrations in maternal plasma and cord blood, pro-
inflammatory cytokine levels (IL-1b, IL-6, and TNF-a) in maternal and cord blood, need for and dosage of
antidepressant medications, and obstetrical outcomes. Analyses will be by intent to treat.
Discussion: This study compares the relative effectiveness of DHA and EPA at preventing depressive symptoms
among pregnant women at risk.
Trial registration: Clinical trial registration number: NCT00711971
Background
Major depressive disorder (MDD) is prevalent among
women of childbearing age. Major depressive disorder is
a significant cause of morbidity and mortality in the
developed world, affecting 20-25% of women at least
once during their lifetime[1]. The primary risk factors
for MDD include female gender, family history of
depression, and previous personal history of depression
[2]. The World Health Organization estimates that
MDD is among the top seven causes of disability-
adjusted life years worldwide [3-5]. In a 30-year projec-
tion of mortality and disability by cause, Murray and
Lopez found MDD to be a leading cause of disability-
adjusted life years (years of potential life loss due to pre-
mature mortality plus years of productive life lost due to
disability) for women globally[4].
Depressive symptoms sufficient to disrupt functioning
have been estimated to occur in 5-25% of women after
delivery [6]. A cross-national review of the literature
found the prevalence rates of postpartum depression to
vary between 0.5% and 24.5%[7]. A cohort study of
depressed mood during pregnancy and after childbirth,
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based on testing with the Edinburgh Postnatal Depres-
sion Scale (EPDS), found that 9.1% of women scored
above the threshold for probable depression at 8 weeks
postpartum [8]. Postpartum depression is associated
with significant functional impairment and with pro-
blems in maternal-infant attachment [9]. Despite the
emphasis given to postpartum depression, antenatal
depression may occur with an equal or greater preva-
lence. A recently published systematic review estimating
the point prevalence of depression during pregnancy
found prevalence rates for depression in the first, sec-
ond, and third trimesters of pregnancy of 7.4%, 12.8%
and 12.0%, respectively [9]. Likewise, a cohort study of
9,028 British women found that the prevalence of
depression at 32 weeks gestation was 13.5% and actually
exceeded the 9.1% depression prevalence at 8 weeks
postpartum[8].
Treatment of depression during pregnancy raises
mothers’ and physicians’ concerns regarding fetal safety.
Many mothers ultimately express reluctance to take
medications during gestation. Indeed, in a population
screening study conducted among pregnant women
attending antenatal clinics at our own institution, only
14% of those with a positive depression screen received
any formal treatment for depression[10]. Women with a
history of postpartum depression in a previous preg-
nancy have a 25-50% risk of depression recurrence [11].
Complications such as preterm birth, preeclampsia,
need for cesarean delivery, and poor pregnancy outcome
may be increased in women experiencing depression
during pregnancy[12]. Women who experience depres-
sion during pregnancy are also at increased risk for per-
sistence or worsening of depression in the postpartum
period[9].
Depression during the critical period of mother-infant
attachment may also adversely affect child neurodeve-
lopment. In a review of the literature concerning infants
of mothers suffering from postpartum depression, Grace
and colleagues found that children of mothers experien-
cing postpartum depression performed less well on cog-
nitive tasks than children on non-depressed mothers at
18 months[13]. Differences in language skills and Pia-
get’s object concepts tasks were noted in particular and
these effects were more pronounced in boys than in
girls. In addition, the authors found that postpartum
depression exerted a modest effect on child behaviors
up to 5 years of life, including distractibility, and antiso-
cial and neurotic behavior at home and in school[13].
Selective serotonin uptake inhibitors (SSRIs) are the
standard treatment for antenatal and postpartum
depression and are widely prescribed during and after
pregnancy[14]. Some, but not all, observational studies
have noted an increased risk for congenital cardiac mal-
formations or pulmonary hypertension with this use of
these medications[15]. SSRIs readily cross the placenta;
Hendrick et al demonstrated that antidepressant and
metabolite concentrations were detectable in 87% of
cord blood samples of infants of mothers who had
received SSRIs [16]. Although neonatal blood levels
were below maternal drug levels, the effects of these
compounds on the developing brain remain unknown.
In a prospective study of newborn neurobehavior, Zes-
kind demonstrated that newborns that had been
exposed to SSRIs in utero had increased motor activity
and tremulousness when compared to unexposed neo-
nates [17]. Exposed neonates also exhibited fewer
changes in behavioral states and fewer different beha-
vioral states. Changes in the proportion of rapid eye
movement sleep were also noted. In another study of
infants born after SSRI exposure in utero, Oberlander
and colleagues observed that neonatal acute pain
response was altered by exposure to SSRIs [18].
Although these observations are of uncertain clinical
significance, they indicate that neurobehavioral changes
are associated with SSRI exposure in utero [19].
In a meta-analysis of available studies on SSRI use
during pregnancy and effects on the fetus and new-
born, Lattimore et al found that infants exposed to
SSRIs in utero are more likely to be low birth weight
and more likely to be admitted to a SCN/NICU at
birth than infants born to mothers not on these medi-
cations[20]. Sanz and colleagues have analyzed a data-
base of reports of neonatal withdrawal symptoms [21].
Paroxetine was associated with neonatal convulsions
and cases of neonatal withdrawal were reported after
exposure to all SSRI drugs. Based upon these data,
Ruchkin and Martin recommended that the threshold
for prescribing these compounds during pregnancy and
in the postpartum should be raised[22]. Concerns
about these compounds have also led to an interest in
complementary and alternative methods of preventing
or treating MDD.
Omega-3 fatty acids, most frequently from fish oil, are
one such complementary and alternative medicine
method. There is a heterogenous literature surrounding
the use of omega-3 fatty acids for mood disorders. Pub-
lished systematic reviews of omega-3 fatty acids for
monotherapy or adjunctive therapy of MDD in non-
pregnant populations have reached conflicting conclu-
sions regarding efficacy and called for further research
[23-25]. While systematic reviews of trials of omega-3
fatty acids in affective disorders by Freeman, [23] Lin,
[25] and Appleton, [26] found that supplementation
produced statistical improvement in mood symptoms,
these authors’ analyses found considerable between-
study heterogeneity, possibly due to differences in the
populations studied, timing of administration, and dif-
fering proportions of the two main omega-3 fatty acids,
Mozurkewich et al. BMC Pregnancy and Childbirth 2011, 11:46
http://www.biomedcentral.com/1471-2393/11/46
Page 2 of 9
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) in the fish oils studied.
Likewise, although omega-3 fatty acids might offer an
alternative to SSRIs for antenatal and postpartum
depression, there has been conflicting evidence of effi-
cacy from the available clinical trials. In a recent sys-
tematic review of placebo-controlled trials of omega-3
fatty acids for prevention or treatment of perinatal
depression, Jans et al did not find benefit for omega-3
supplementation in their total analysis. However, there
was some evidence of effectiveness among women with
MDD[27]. A recent large placebo-controlled randomized
controlled trial (RCT) of DHA for prevention of perina-
tal depression among pregnant women not selected by
risk status did not show a benefit of DHA for this indi-
cation[28].
One possible reason for the heterogeneity of results of
the available trials may be differing effectiveness of
DHA and EPA. Two systematic reviews of published
RCT’s have found EPA but not DHA to be effective in
alleviating depressive symptoms[29,30]. Thus the
Omega-3 fatty acids subcommittee assembled by the
Committee on Research on Psychiatric Treatments of
the American Psychiatric Association has called for
further randomized controlled trials of omega-3 fatty
acids for mood disorders, and in particular comparisons
of EPA and DHA [23]. To our knowledge, the proposed
study is the first to directly compare EPA and DHA-rich
fish oils in a pregnant population.
Methods
Aims
The aim of this study is to determine whether EPA or
DHA will prevent pregnancy-related depressive symp-
toms. We hypothesize that EPA-rich fish oil supplemen-
tation and DHA-rich fish oil supplementation will
reduce the risk of antenatal and postpartum depressive
symptoms in women who are at elevated risk for
depression based on a previous history of major depres-
sive disorder, a previous history of postpartum depres-
sion, or an Edinburgh Postnatal Depression Scale
(EPDS) score between 9 and 19 in early pregnancy. The
study will also directly compare the effects of EPA and
DHA on depressive symptoms as measured by the Beck
Depression Inventory score. In addition we hypothesize
that fewer pregnant women assigned to the fish oil sup-
plementation will require treatment with antidepressant
medications and if medicated, a lower total dose will be
required than for women receiving placebo. We will
recruit pregnant women who are between 12-20 weeks
gestation and will follow them through their pregnancies
and up to 6 weeks postpartum. The women participat-
ing in this study will be receiving prenatal care at two
health systems in southeastern Michigan, the University
of Michigan Hospitals and Clinics and St. Joseph Mercy
Health System/Integrated Health Associates. These
health systems are located in Ann Arbor, Michigan and
Ypsilanti, Michigan and the surrounding communities.
This study also has three secondary aims that will
generate preliminary data on possible mechanisms of
action of EPA and DHA in mental health. First, we will
examine the relationship between EPA and DHA,
maternal plasma fatty acid levels, and symptoms of
depression. Second, we will explore whether EPA and
DHA reduce depressive symptoms by reducing synthesis
of pro-inflammatory cytokines IL-6, IL-1b, and TNF-a.
Third, we will examine the relationship between EPA
and DHA and standard pregnancy outcomes, including
birth weight and length of gestation.
Participants/Eligibility Criteria
To be eligible to participate in the study, women must
be 18 years of age or older, have a confirmed, live,
intrauterine pregnancy of greater than 12 weeks gesta-
tion but less than 20 weeks gestation, and be enrolled in
prenatal care at one of the two participating health sys-
tems. They must be planning to deliver at one of the
two participating hospitals and plan to remain in the
southeastern Michigan area through 6 weeks after deliv-
ery. To qualify for the study, women must be at risk for
depression, based on (i) a history of MDD, (ii) a history
of postpartum depression, or (iii) an EPDS score
between 9 and 19.
Women will be excluded from participating in the
study if they are currently taking an omega-3 fatty acid
supplement; taking antidepressant or other psychiatric
medications; using therapeutic or prophylactic anticoa-
gulation medication; or consuming more than 2 fish
meals per week. In addition, pregnant women with a
diagnosis of current major depressive disorder, or other
psychiatric diagnoses, including current substance abuse,
schizophrenia, and bipolar disorder will be excluded
from study. Pregnant women with a history of bleeding
disorder such as von Willebrand’s Disease will also be
excluded.
Recruitment, Randomization, and Collection of Baseline
Data
Screening for depression using the EPDS screen is car-
ried out as standard clinical practice at most, but not
all, of the participating clinical care sites. Clinicians car-
ing for pregnant women use the EPDS to identify
women at risk and to facilitate mental health referrals.
We will identify our eligible population of women with
EPDS 9-19 or a past history of MDD through a variety
of mechanisms, including health care provider referrals,
advertisements, a pregnancy and mental health research
registry, and a screening questionnaire and “permission
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to determine eligibility” form administered at the time
of visits to the obstetrician or midwife, or to an obstetri-
cal ultrasound unit.
The EPDS is a widely used, valid and reliable 10 item
measure of perinatal mood[31]. This scale was chosen
because it is less reliant on somatic complaints than
other depression scales, and somatic complaints are very
common in normal pregnancy. The EPDS is self-admi-
nistered and may be scored by a wide range of health
care workers. The EPDS has also been shown to be
responsive to mood changes as a function of treatment
[32]. A cut off score of 12 has been recommended for
detecting the presence of MDD, with sensitivities found
to be .68 - 1.0 and specificities of .49-1.0[33]. EPDS
scores above 9 may indicate subclinical depression and
risk for later development of MDD[34].
Those eligible women who agree to be contacted will
be given information about the study, and offered study
participation. All eligible women are informed of the
risks and benefits of study participation, and reminded
that study participation is voluntary. Full written
informed consent will be solicited. Women who agree
to participate will undergo a final determination of elig-
ibility with administration of the Mini International
Neuropsychiatric Interview (MINI), either by phone or
in person. The MINI will identify women with current
MDD or other major psychiatric diagnoses or substance
dependence. These women are not eligible for the study
and will be excluded from the sample population prior
to randomization. They will be offered referral informa-
tion for appropriate mental health care. Women meet-
ing all eligibility criteria will be randomized and will
attend 4 study visits.
Randomization will be carried out by use of a random
number table maintained in the University of Michigan
Investigational Drug Service (IDS). The research team
will be blinded to the results of the randomization. The
research team will provide the IDS staff with a list of
unique identifying numbers prior to the start of recruit-
ment and, at the time of randomization, will inform the
staff of the study identification number of each partici-
pant to be randomized. The IDS staff will then rando-
mize participants to one of three study arms using a
random number table: intervention #1, intervention #2,
or placebo and will maintain randomization records
until the last participant has completed the protocol.
The IDS will dispense all study supplement which will
consist of either: a) EPA-rich fish oil supplement (1060
mg EPA plus 274 mg DHA) (intervention #1); b) DHA-
rich fish oil supplement (900 mg DHA plus 180 mg
EPA) (intervention #2); and c) a placebo (control arm).
Because the EPA and DHA capsules are not identical in
appearance, all subjects will receive some placebo cap-
sules. For the EPA group, this will involve taking 2 large
EPA capsules and 4 small placebo capsules daily; the
DHA group will take 2 large placebo capsules and 4
small DHA capsules daily. The placebo group will take
2 large placebo capsules and 4 small placebo capsules
daily.
The intervention supplements and placebo have been
provided by Nordic Naturals in Watsonville, California.
The EPA-rich fish oil (ProEPAXtra, Nordic Naturals,
Watsonville, CA) planned as intervention #1 in this
study contains an approximate 4:1 ratio of EPA to DHA
(1060 mg EPA plus 274 mg DHA). The DHA-rich oil
(ProDHA, Nordic Naturals, Watsonville, CA) to be stu-
died as intervention #2 contains DHA and EPA in an
approximate 4:1 ratio (900 mg DHA plus 180 mg EPA).
We chose these fish oil supplements because of their
EPA-rich and DHA-rich compositions. The control
group (intervention #3) will receive a placebo that will
contain 98% soybean oil and 1% each of lemon and fish
oil and will be indistinguishable in appearance and taste
from the active supplements. The supplements will be
molecularly distilled and free of industrial contaminants,
mercury, and organochlorines.
Study Visits
As much as possible, the four study visits will be coordi-
nated with the subjects’ routine prenatal care or ultra-
sound appointments. Visit #1 will occur between 12 and
20 weeks’ gestation. Full written informed consent will
be obtained. Baseline demographic and past medical and
obstetrical history data will be collected. The baseline
BDI (Beck Depression Inventory) will be administered.
After a 3-hour fast, subjects will have their blood drawn
to measure their baseline omega-3 fatty acid and proin-
flammatory cytokine levels (IL-1b, IL-6, and TNF-a).
Subjects will be given a 3 month supply of the study
supplement at this visit. Subjects will be instructed to
take three capsules twice daily with meals and to return
all unused capsules to the research team at their next
study visit.
The second study visit will take place between 26 and
28 weeks gestation. During this visit, the BDI will be
completed and the MINI will be re-administered to
assess for MDD, suicidal ideation and psychiatric co-
morbidity. The subjects will return their prescriptions to
the study staff and all unused capsules will be counted.
A two month supply of the study supplement will be
given to each subject.
The third study visit will take place between 34 and 36
weeks gestation. During this morning visit, the BDI will
be completed and the MINI will be re-administered. In
addition, a second fasting blood sample will be obtained
to measure the participant’s omega-3 fatty acid levels
and proinflammatory cytokine levels (IL-1b, IL-6, and
TNF-a). At this visit, a three-month supply will be
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dispensed in order to provide women with sufficient
doses until the postpartum visit. Each participant will be
provided with a packet containing sterile tubes for col-
lection of cord blood. Participants will be instructed to
bring this packet with them to the hospital when they
present to the Labor and Delivery unit.
When the subject presents for delivery, clinical staff
will be notified that the patient is a study participant.
After delivery of the baby, cord blood will be collected
and proinflammatory cytokine levels and fatty acid levels
will be assayed (visit #4).
The final study visit will take place at the participant’s
6 week postpartum check-up. During this visit, the BDI
will be completed and the MINI will be re-administered.
Participants will receive $20 and a parking voucher for
each study visit that they attend.
Capsule compliance will be monitored by pill counts.
Adherence to the study protocol will also be ascertained
by measurement of omega-3 fatty acid concentrations in
maternal plasma at baseline and at 34-36 weeks’
gestation.
Study participants who score above at or above a 20
on the BDI or who meet criteria for MDD on the MINI
at any time during the study period will be referred for
appropriate management with a mental health provider,
who may prescribe antidepressant medications if indi-
cated. In this case, the participant will be instructed to
continue with the study intervention during treatment
and to complete all study visits. Any subject expressing
suicidal ideation will be escorted to the psychiatric
emergency department.
Results/Outcomes
Primary Outcome Measure
The primary outcome of interest in the proposed study
is the participant’s BDI score at 6 weeks postpartum.
The BDI is widely accepted and will be used to measure
the severity of depressive symptoms during pregnancy
and in the postpartum period. It was first introduced by
Dr. Aaron Beck and colleagues in 1961 (BDI-I) and con-
sists of 21 questions about how the participant was feel-
ing in the last week[35]. Each set of at least four
possible answer choices range in increasing intensity.
The questions touch on depressive symptoms such as
hopelessness and irritability, cognitions such as guilt or
feelings of being punished, as well as physical symptoms
such as fatigue, weight loss, and lack of interest in sex-
ual intercourse.
The test characteristics of the BDI as a depression
screen among pregnant populations have been well-
characterized[36,37]. In a longitudinal study among 105
pregnant women attending an urban antenatal clinic,
Holcomb found the BDI to be a rapid and sensitive
screening test for depression[37]. The standard cutoffs
for the BDI are as follows: 0-9 for no significant depres-
sive symptoms; 10-19 for mild to moderate depression;
20-29 for moderate to severe depression; and 30-63 for
severe depression. Higher total scores indicate more
severe depressive symptoms. The BDI has been used
widely in clinical research and especially in pregnant
populations[37-39] and has high internal consistency
[40]. The questionnaire takes no more than 10 minutes
to complete and is prepared at a 5th to 6th grade reading
level.
For the proposed study, the BDI will be administered
at baseline, 26-28 and 34-36 weeks gestation, and at 6
weeks postpartum. As our primary outcome of interest,
depressive symptoms will be measured as a continuous
variable and reported in descriptive and multivariable
analyses as means and standard deviations.
Secondary Outcomes
Secondary outcomes we will evaluate include a) the
need for depression-related treatment and antidepres-
sant medication during and after pregnancy; b) depres-
sive symptoms, as measured by the BDI, at 26-28 and
34-36 weeks gestation; c) changes in omega-3 fatty acid
concentrations in maternal plasma at baseline (<20
weeks gestation) and at 34-36 weeks gestation; d)
changes in levels of proinflammatory cytokines (IL-1b,
IL-6, and TNF-a ) at baseline and at 34-36 weeks gesta-
tion; and e) standard obstetric outcomes including
length of gestation, birth weight, Apgar score, mode of
delivery, blood loss at delivery, gestational hypertension,
gestational diabetes, and preeclampsia. Neonatal out-
comes, including cord umbilical pH, length of stay,
NICU admission, and antibiotic administration will be
recorded as well. We will also evaluate the effect of
maternal omega-3 fatty acid supplementation on cord
blood fatty acid levels as well as fetal synthesis of proin-
flammatory cytokines IL-6, IL-1b, and TNF-a.
Information on pregnancy outcomes will be extracted
from the electronic medical record. Preterm birth will
be defined as delivery before 37 completed weeks’ gesta-
tion and post-term gestation will be defined as delivery
at or beyond 42 completed weeks’ gestation. Birth
weight, Apgar scores, mode of labor onset (spontaneous
or induced), mode of delivery, and estimated blood loss
at delivery are all available in the electronic record.
Blood loss at delivery is routinely estimated by the deli-
vering physician or midwife. Gestational hypertension
will be defined as systolic blood pressure (BP) elevation
≥30 mm Hg or diastolic BP elevation >15 mm Hg com-
pared to early pregnancy BP. Preeclampsia will be
defined by blood pressure criteria noted above plus >1+
proteinuria on urine dipstick or > 300 mg protein on 24
hour urine collection. Gestational diabetes will be diag-
nosed based on a 1 hour glucose after a 50 gm glucose
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load of ≥200 or 2 abnormal values on a 3 hour glucose
tolerance test.
Sample Size Considerations
We hypothesize that (i) fish oil supplementation will
reduce the severity of depressive symptoms in the post-
partum period among women at risk and that the (ii)
EPA-rich fish oil (intervention #1) and DHA-rich fish
oil (intervention #2) will be equally efficacious in redu-
cing depressive symptoms. Our sample size calculation
is based on the premise that fish oil supplementation of
either the EPA-rich or DHA-rich dose will result in a 50
percent reduction in the mean BDI score at 6 weeks
postpartum. Sample size calculations were generated in
nQuery Advisor Version 6.01 based on data from a pre-
vious study conducted among the target population by
one of the co-investigators, Dr. Delia Vazquez. In that
observational study, she observed a mean BDI score of
8.4 with a standard deviation of 6.4 among postpartum
mothers at risk for depression. Assuming a significance
level of 0.05, a one-way analysis of variance test, a var-
iance of means (variance of the individual group means)
of 3.920, a standard deviation of 6.4, and an effect size
(the index of the separation expected among the
observed means) of 0.0957, we will need to recruit 105
pregnant women (35 pregnant women in each of the
three groups) to have 80% power to detect at least one
group difference in the mean BDI score. We propose to
recruit 126 pregnant women to account for the possibi-
lity of up to 10% study dropout and 10% initiating anti-
depressant therapy during the study period (to provide
sufficient numbers for subgroup analyses).
Our decision to hypothesize a 50% reduction in the
mean BDI score between intervention and control
groups is based on results from published studies. Free-
man and colleagues recently conducted two clinical
trials[41,42] of omega-3 fatty acid supplementation and
perinatal depression, using the EPDS as their primary
measure of depressive symptomatology and reported a
51% and 41% reduction in EPDS score over an 8 week
study period. A comparable study in a non-pregnant
population demonstrated a similar effect size[43].
Analysis Plan
We propose to recruit 126 women to examine the effect
of a prenatal omega-3 fatty acid supplementation inter-
vention on the risk of postpartum depressive symptoms
at 6 weeks postpartum. Data will be prospectively col-
lected via in-person interview, blood samples for serolo-
gic testing, and electronic medical chart abstraction.
Information obtained from in-person interview and
from chart abstraction will be initially completed by
paper by a member of the research team and then trans-
ferred to a customized study database. The data files will
be password protected and kept in a secure location on
our network server. All statistical analyses will be per-
formed using Statistical Analysis Software (SAS) Version
9.1 (SAS Institute, Inc., Cary, NC).
Covariate Assessment
Other experiences of the participant that might influ-
ence depressive symptomatology must be considered as
potential confounders. These include other exposures
that occur during the prenatal and postpartum period.
In addition to detailed information on the intervention
and outcomes of interest, we will collect a detailed
demographic, behavioral, dietary, and medical history
from each participant at the time of study enrollment
and review the participant’s medical record and docu-
ment any complications incurred during pregnancy.
Descriptive Analyses
Once data have been collected, descriptive statistics
(means, standard deviations, frequencies, proportions,
and graphical displays) will be computed for all study
variables. The distributions of outcome variables will be
assessed to determine if distributional assumptions are
valid. Decisions will be made at this time about the
creation of category boundaries for certain continuous
covariates, using well-established cut-points where
appropriate. All analyses will be done on an intent-to-
treat basis. Baseline analyses will be performed to deter-
mine if the three study groups are comparable or not
with respect to various variables including age, parity,
and body weight. If any of the baseline variables are
shown to be different across the three groups, any out-
come comparisons across the three groups will be
adjusted for the potential confounding effect of these
variables. In all analyses, we plan to control for possible
confounders, and covariates that change the coefficient
of interest by more than 10% will be retained in the
final multivariable model.
Multivariable Analyses
To assess the effectiveness of a prenatal omega-3 fatty
acid supplementation intervention in reducing the inci-
dence and severity of depressive symptoms during preg-
nancy and up to 6 weeks postpartum, a one-way
analysis of variance (ANOVA) with repeated measures
will be used via the MIXED procedure in SAS. A one-
way ANOVA has the advantage of testing whether there
are any differences between the three groups with a sin-
gle probability associated with the test. The hypothesis
tested is that all groups have the same mean. We will
have one within factor (time) and one between factor
(supplement group). The ANOVA will allow us to assess
the significance of the two main effects as well as if
interaction is present, adjusting for potential
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confounding variables. Moreover, as a repeated mea-
sures design, it will allow us to use all four BDI assess-
ments, which in turn will provide more detailed
information about the trends over time than one or two
assessments would. Lastly, we will be able to look at
intermediate outcomes of interest, such as the effect of
the prenatal omega-3 fatty acid supplementation inter-
vention during pregnancy, using only the three BDI
assessments performed during the prenatal period in
our one-way ANOVA with repeated measures model.
Women who initiate antidepressant therapy during the
study period will remain in the study for its duration.
However, it will be necessary to take this change in
treatment into account in our multivariable analyses.
Thus, in addition to the above mentioned analyses, we
will also perform a subgroup analysis among those who
were not taking antidepressants during the study period.
We will also test whether therapy could be a confounder
or effect modifier of the effect of fish oil supplementa-
tion on depressive symptomtaology over the entire
study cohort.
All multivariable analyses will be performed using the
MIXED procedure in SAS, as this procedure allows for
missing data. While the research team will make every
effort to collect data from all participants at all four
time points during the study period, it is possible that a
participant might miss one or two study visits. The
methodological approach chosen for this proposal allows
for some flexibility with the analyses performed. For
example, comparisons will be drawn between baseline
and 6 week postpartum BDI scores solely, as well as
after taking into account the assessments drawn at 26-
28 and 34-36 weeks gestation. Unlike the general linear
models (GLM) procedure in SAS, the MIXED procedure
does not remove all data for any subject that does not
have complete data. Rather, all study participants are
retained in the analysis and all available information is
used.
Other Planned Exploratory Analyses
To evaluate the effect of fish oil supplementation on
omega-3 fatty acid concentrations in maternal blood, we
will use a mixed effect model for longitudinal data
because the omega-3 fatty acid concentrations will be
measured twice for each participant (at baseline and at
34-36 weeks gestation). Using this model, we can assess
both the time averaged difference in the concentration
between the three groups as well as the change in the
concentration over the two measurement times between
the three groups. To evaluate the effect of fish oil sup-
plementation on the proinflammatory cytokines refer-
enced, we will use a mixed effect model for longitudinal
data because each proinflammatory cytokine level will
be measured twice for each participant (at baseline and
at 34-36 weeks gestation). Using this model, we can
assess both the time averaged difference in the levels
between the three groups as well as the change in con-
centration over the two measurement times between the
three groups. To evaluate the effect of fish oil supple-
mentation on standard obstetrical outcomes including
but not limited to length of gestation, birth weight,
Apgar score, mode of delivery, blood loss at delivery,
and preeclampsia, we will use multiple regression for
continuous outcomes variables and logistic regression
for dichotomous outcome variables, and in either of
these approaches, an indicator for fish oil supplementa-
tion will be the primary independent variable.
The exploratory aims are intended to generate preli-
minary data elucidating the possible mechanism of
action of fish oil supplementation in the prevention of
depression in pregnancy and the postpartum period. In
particular, the role of fish oil in inhibiting production of
proinflammatory cytokines may provide an explanation
for the observed link between depression in pregnancy
and preterm birth, a condition known to be associated
with inflammation. Although we will be unable to defi-
nitively explore these relationships in the proposed
study, we intend for these aspects of the study design to
generate preliminary data which will allow us to refine
our dosing, expected effect sizes, and hypotheses for a
larger, multicenter study of the effectiveness of fish oil
in prevention of major depression in pregnancy and
postpartum.
Discussion
The proposed study will assess the effect of two fish oil
supplements on depressive symptomatology in an at-risk
population through a randomized controlled design.
Strengths to this study include its double-blind, placebo-
controlled design and its inclusion of two intervention
groups to test both an EPA-rich and a DHA-rich sup-
plement. To our knowledge, the proposed study is the
first to directly compare these two fish oils in a preg-
nant population. Results of previous systematic reviews
indicate that differences in fish oil composition may
account for the heterogeneity of the observed results of
prevention and treatment trials for depression[29,30].
However, this hypothesis has not been previously tested
in a RCT comparing both interventions.
The proposed study has the potential to impact clini-
cal care for pregnant women at risk for depression dur-
ing and after pregnancy. There is a significant burden of
disease associated with major depression, and although
depression during and following pregnancy occurs at a
frequency similar to preeclampsia (5-8%) and preterm
birth (11%), it receives much less clinical attention. The
disability associated with depression is as great as the
disability of other chronic diseases such as hypertension,
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diabetes, and rheumatoid arthritis[44]. Maternal depres-
sion during pregnancy may also constitute a risk factor
for suboptimal neurobehavioral development of the
child. Dietary supplementation with molecularly distilled
omega-3 fatty acid preparations may provide a safe and
well-tolerated means for pregnant women to reduce
their risk for depression.
Details of Ethics Approval
This study has been approved by the institutional
review boards of the University of Michigan Health Sys-
tem and the St. Joseph Mercy Health System. This trial
is registered with the Cochrane Clinical Trials Registry
and at: http://clinicaltrials.gov/ct2/results?term=Mozur-
kewich The study is being carried out under a United
States Food and Drug Administration (FDA) Investiga-
tional New Drug Application for the supplements under
study: ProEPA Xtra, and Pro DHA. There is a three per-
son data safety monitoring committee (DSMC) that
meets quarterly. Current members of the DSMB are
Drs. Barbara Luke, Charles Neal, and Dwight Rouse. Dr.
Mel Barclay served on the committee until his death in
2010.
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